Company stock prices before public announcements of oncology trial results

Prior knowledge of phase III clinical trials of new drugs and Food and Drug Administration (FDA) regulatory decisions may affect the price of a drug company's stock according to a study published September 26 in the Journal of the National Cancer Institute.

Read the whole article on Physorg

More from Physorg